TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade

Show full item record



Permalink

http://hdl.handle.net/10138/313935

Citation

Cervera-Carrascon , V , Siurala , M , Santos , J M , Havunen , R , Tähtinen , S , Karell , P , Sorsa , S , Kanerva , A & Hemminki , A 2018 , ' TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade ' , OncoImmunology , vol. 7 , no. 5 , 1412902 . https://doi.org/10.1080/2162402X.2017.1412902

Title: TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
Author: Cervera-Carrascon, V.; Siurala, M.; Santos, J. M.; Havunen, R.; Tähtinen, S.; Karell, P.; Sorsa, S.; Kanerva, A.; Hemminki, A.
Contributor: University of Helsinki, Clinicum
University of Helsinki, University of Helsinki
University of Helsinki, Department of Oncology
University of Helsinki, Clinicum
University of Helsinki, Department of Oncology
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Clinicum
University of Helsinki, Akseli Eetu Hemminki / Principal Investigator
University of Helsinki, Clinicum
Date: 2018
Language: eng
Number of pages: 11
Belongs to series: OncoImmunology
ISSN: 2162-402X
URI: http://hdl.handle.net/10138/313935
Abstract: Releasing the patient's immune system against their own malignancy by the use of checkpoint inhibitors is delivering promising results. However, only a subset of patients currently benefit from them. One major limitation of these therapies relates to the inability of T cells to detect or penetrate into the tumor resulting in unresponsiveness to checkpoint inhibition. Virotherapy is an attractive tool for enabling checkpoint inhibitors as viruses are naturally recognized by innate defense elements which draws the attention of the immune system. Besides their intrinsic immune stimulating properties, the adenoviruses used here are armed to express tumor necrosis factor alpha (TNFa) and interleukin-2 (IL-2). These cytokines result in immunological danger signaling and multiple appealing T-cell effects, including trafficking, activation and propagation. When these viruses were injected into B16.OVA melanoma tumors in animals concomitantly receiving programmed cell-death protein 1 (PD-1) blocking antibodies both tumor growth control (p <0.0001) and overall survival (p <0.01) were improved. In this set-up, the addition of adoptive cell therapy with OT-I lymphocytes did not increase efficacy further. When virus injections were initiated before antibody treatment in a prime-boost approach, 100% of tumors regressed completely and all mice survived. Viral expression of IL2 and TNFa altered the cytokine balance in the tumor microenvironment towards Th1 and increased the intratumoral proportion of CD8+ and conventional CD4+ T cells. These preclinical studies provide the rationale and schedule for a clinical trial where oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) is used in melanoma patients receiving an anti-PD-1 antibody.
Subject: Immunotherapy
Virotherapy
Immunovirotherapy
Checkpoint blockade
Adoptive cell therapy
Adenovirus
Melanoma
Solid tumors
anti-PD1
T cell therapy
Adoptive T cell therapies
Models of immunostimulation
Therapeutic antibodies
T-CELL THERAPY
NECROSIS-FACTOR-ALPHA
ONCOLYTIC ADENOVIRUS
INFILTRATING LYMPHOCYTES
TALIMOGENE LAHERPAREPVEC
CANCER-IMMUNOTHERAPY
INHIBITORY RECEPTORS
IDENTITY CRISIS
TUMOR
MELANOMA
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Cervera_Carrasc ... vised_ACCEPTED_DRAFT_1.pdf 1.734Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record